1 / 66

Number of ICAP-supported sites by activity, March 2009 (n=839)

Number of ICAP-supported sites by activity, March 2009 (n=839). Number of sites. Number of ICAP-supported sites by country, March 2009 (n=839). Number of sites. What: Collects program and facility information on ICAP-supported care and treatment programs semi-annually

marsden-lopez
Download Presentation

Number of ICAP-supported sites by activity, March 2009 (n=839)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Number of ICAP-supported sites by activity, March 2009 (n=839) Number of sites

  2. Number ofICAP-supported sites by country, March 2009 (n=839) Number of sites

  3. What: Collects program and facility information on ICAP-supported care and treatment programs semi-annually Purpose: To describe the scope, diversity, and comprehensiveness of ICAP-supported care and treatment programs, and evaluate multi-level factors that influence program performance and patient-level outcomes Program and Facility Characteristics Tracking System (PFaCTS)

  4. Location and type of ICAP-supported HIV care and treatment sites (n=341) n=149 n=192 % sites

  5. Proportion of ICAP-supported HIV care and treatment sites offering HIV-related services on site (n=341) % sites with service

  6. Proportion of ICAP-supported HIV care and treatment sites offering HIV-related services on site by number of services offered (n=341)

  7. Proportion of ICAP-supported HIV care and treatment sites offering ≥4 HIV-related services on site (n=338) ICAP Average =76% % sites with ≥4 services

  8. Proportion of ICAP-supported HIV care and treatment sites offering on-site patient support services by type of service offered (n=323) % sites with service

  9. Proportion of ICAP-supported HIV care and treatment sites offering on-site patient support services by number of services offered (n=323)

  10. Proportion of ICAP-supported HIV care and treatment sites with ≥4 on-site patient support services (n=241) ICAP Average =45% % of sites with ≥ 4 services

  11. Proportion of ICAP-supported HIV care and treatment sites with access to laboratory assays (n=342) % sites

  12. Proportion of ICAP-supported HIV care and treatment sites with access to laboratory assays by number of assays (n=336)

  13. Proportion of ICAP-supported HIV care and treatment sites with access to key HIV-related laboratory assays (n=342) ICAP Average =98% % sites

  14. Proportion of ICAP-supported HIV care and treatment sites with access to PCR laboratory assays (n=325) ICAP Average =92% % sites

  15. Mean number of full-time health care providers at ICAP-supported HIV care and treatment sites (n=348) Mean number of providers

  16. Mean number of outreach workers at ICAP-supported HIV care and treatment sites (n=183) Mean number of outreach workers

  17. Trend in proportion of ICAP-supported HIV care and treatment sites offering on-site patient support services (n=175) % sites

  18. Trend in proportion of ICAP-supported HIV care and treatment sites offering prevention services(n=71) % sites

  19. Proportion of ART patients in sub-Saharan Africa that initiated ART at an ICAP-supported site, December 2007 % of all patients on ART Sub-Saharan countries where ICAP works

  20. HIV care and treatment services

  21. Cumulative enrollment in ICAP-supported HIV care and treatment programs (currently reporting) 436 sites Cote d’Ivoire Swaziland Nigeria, Zambia Number of facilities Number of patients Lesotho, Rwanda S. Africa, Tanzania 613,005 in care Ethiopia Mozambique 298,668on ART

  22. Cumulative pediatric enrollment in ICAP-supported HIV care and treatment programs (currently reporting) 436 sites Cote d’Ivoire Swaziland Nigeria, Zambia 63,364 in care Number of facilities Number of patients Lesotho, Rwanda S. Africa, Tanzania Ethiopia Mozambique 28,031 on ART

  23. Cumulative enrollment in HIV care in ICAP-supported HIV care and treatment programs by country(n=613,005) Cote d’Ivoire Swaziland Zambia Nigeria Lesotho Tanzania Number of patients Kenya Rwanda Ethiopia South Africa Mozambique

  24. Cumulative enrollment on ART at ICAP-supported HIV care and treatment programs by country (n=298,668) Swaziland Zambia Cote d’Ivoire Nigeria Lesotho Tanzania Number of patients Kenya Rwanda Ethiopia South Africa Mozambique

  25. Cumulative person-years on ART at ICAP-supported care and treatment programs, as of March 2009 Cumulative person-years on ART

  26. Cumulative and current enrollment in ART care at ICAP-supported HIV care and treatment programsas of March 2009 (n= 298,668) Cumulative initiating ART Lost to follow up Reported dead Number of patients ART patients retained in care

  27. Cumulative enrollment in ICAP-supported HIV care and treatment programs by ART status, age, and sex, as of March 2009 Total ART enrollment (n=298,668) Total care enrollment (n=613,005) Men 15+ Women 15+ Children <15 Children <15 Men 15+ Women 15+

  28. Proportion of patients ever enrolled in HIV care who initiated ART in ICAP-supported care and treatment programs as of March 2009 % patients initiating ART n=71,370 n=51,169 n=613,005 n=10,073 n=36,875 n=41,916 n= 42,097 n=79,908 n=35,517 n=2,605 n=176,425 n=72,050

  29. Cumulative enrollment in ICAP-supported HIV care and treatment programs by age and sex as of March 2009 n=298,668 n=314,337 n=613,005 % patients

  30. Cumulative HIV care enrollment of women and children in ICAP-supported HIV care and treatment programs as of March 2009 % patients in HIV care n=613,005 n=71,370 n=41,916 n=36,875 n=10,073 n=51,169 n=79,908 n= 42,097 n=2,605 n=35,517 n=72,050 n=176,425

  31. Cumulative ART enrollment by women and children in ICAP-supported HIV care and treatment programs as of March 2009 % patients on ART n=32,227 n=298,668 n=18,096 n=20,399 n=22,989 n= 35,174 n=4,098 n=41,022 n=22,996 n=1,585 n=42,344 n=57,338

  32. Cumulative pediatric HIV care enrollment in ICAP supported HIV care and treatment programs, as of March 2009 n=97 n=6,391 n=4,455 n=7,986 n=3,091 n=3,786 n=15,236 n=1,213 n=9,966 n=5,374 n=63,364 n=5,769 % pediatric patients in HIV care

  33. Cumulative pediatric ART enrollment in ICAP-supported HIV care and treatment programs as of December 2008 n=3,529 n=4,990 n=3,255 n=2,842 n=4,009 n=680 n=1,394 n=2,409 n=58 n=28,031 n=1,405 n=3,460 % pediatric patients on ART

  34. ART initiation among patients eligible for ART in ICAP-supported HIV care and treatment programs, January-March 2009 n=376 n=285 n=5,369 n=3,058 n=1,447 n=3,740 n=680 n=2,720 n=2,002 n=3,230 n=25,366 n=2,115 % patients eligible for ART

  35. ART regimens distributed in ICAP-supported HIV care and treatment programs, January-March 2009

  36. ART regimens distributed to adults in ICAP-supported HIV care and treatment programs, January-March 2009 * In South Africa, D4T-3TC-LPV/r , ZDV-ddl-LPV/r , and ABC-ddl-LPV/r are prescribed as a first-line regimen for pediatric patients.

  37. ART regimens distributed to children in ICAP-supported HIV care and treatment programs, January-March 2009

  38. Proportion of patients with CD4 count at baseline, 6, and 12 months after ART initiation, as of March 2009 % patients with CD4 count n=7,153 10,581 n=5,712 n=7,759 n=22,936 n=9,162 n=7,682 n=26,178 n=97,163

  39. Average median CD4 count at baseline, 6 and 12 months after ART initiation, as of March 2009 CD4 Cell Count (cells/ul)

  40. Change in Median CD4 count (cells/µL) at 6 and12 months of ART, as of March 2009 Change in median CD4 count

  41. Status of ART patients at ICAP-supported HIV care and treatment programs as of March 2009 (n= 298,668) 94.5 per 1,000 person-years 51.7 per 1,000 person-years 5.9 per 1,000 person-years *Includes patients who transferred out while on ART.

  42. Reasons for ART discontinuation in ICAP-supported HIV care and treatment programs as of March 2009 n=7,787 n=5,165 n=65 n=6,520 n=12,335 n=2,577 n=3.202 n=1,861 n=8,540 n=7,083 n=248

  43. PMTCT services

  44. Pregnant women counseled and tested inICAP-supported PMTCT programs, as of March 2009 # of Women

  45. Pregnant women counseled and tested inICAP-supported PMTCT programs as of March 2009 % Women

  46. Pregnant women counseled and tested inICAP-supported PMTCT programs over time 1st ANC 83,677 Counseled78,956 Tested 74,330 HIV Positive 5,096 ART Prophylaxis 3,739

  47. Pregnant women counseled and tested inICAP-supported PMTCT programs over time % Women n=38.965 n=83,499 n=83,577 n=33,827 n=50,099 n=59,322 n=60,520 n=67,608 First ANC

  48. Pregnant women counseled and tested inICAP-supported PMTCT programs by country as of March 2009 % Women n=32,835 n=9,545 n=7,504 n=42,577 n=189,701 First ANC n=75,619 n=124,536

  49. Type of ART prophylaxis at ICAP-supported PMTCT programs, as of March 2009 n=22,154 n=2,181 n=10,144 n=738 n=411 n=5,484 n=1,852 n=1,344 % Women

  50. Type of ART prophylaxis at ICAP-supported PMTCT programs, April 2007 – March 2009 n=1,216 n=3,587 n=2,247 n=2,536 n=2,931 n=1,932 n=3,966 n=3,739 % Women

More Related